Association between white blood cell count and non-alcoholic fatty liver disease in urban Han Chinese: A prospective cohort study

BMJ Open

Volumn 6, Issue 6, 2016, Pages

  Wang, Shukang ^a   Zhang, Chengqi ^b   Zhang, Guang ^b   Yuan, Zhongshang ^a   Liu, Yanxun ^a   Ding, Lijie ^a   Sun, Xiubin ^a   Jia, Hongying ^c   Xue, Fuzhong ^a  

^a SHANDONG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^c THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

Author keywords

Chinese adults; longitudinal cohort study; Non alcoholic Fatty Liver Disease (NAFLD); White blood cell (WBC)

Indexed keywords

ALBUMIN; GLOBIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN; TRIACYLGLYCEROL; LIPID;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; CHINESE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DIASTOLIC BLOOD PRESSURE; EXERCISE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HAN CHINESE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LABORATORY TEST; LEUKOCYTE COUNT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; NONALCOHOLIC FATTY LIVER; PREVALENCE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URBAN AREA; URBAN POPULATION; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; BLOOD PRESSURE; CHINA; MIDDLE AGED; RISK FACTOR;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; BODY MASS INDEX; CHINA; FEMALE; HUMANS; HYPERGLYCEMIA; HYPERTENSION; LEUKOCYTE COUNT; LIPIDS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84974676978     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-010342     Document Type: Article

References (55)

1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-Alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-23.
2. Blachier M, Leleu H, Peck-Radosavljevic M, et al. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013;58:593-608.
3. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005;288:E462-8.
4. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010;53:372-84.
5. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011;9:524-30.
6. Fan JG, Saibara T, Chitturi S, et al. What are the risk factors and settings for non-Alcoholic fatty liver disease in Asia-Pacific? J Gastroenterol Hepatol 2007;22:794-800.
7. Fan JG, Farrell GC. Epidemiology of non-Alcoholic fatty liver disease in China. J Hepatol 2009;50:204-10.
8. Li Z, Xue J, Chen P, et al. Prevalence of nonalcoholic fatty liver disease in mainland of China: a meta-Analysis of published studies. J Gastroenterol Hepatol 2014;29:42-51.
9. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-21.
10. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004;8:521-33.
11. Asrih M, Jornayvaz FR. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. J Endocrinol 2013;218:R25-36.
12. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005;143:722-8.
13. Hamaguchi M, Kojima T, Takeda N, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007;13:1579-84.
14. Bae JC, Rhee EJ, Lee WY, et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study. Diabetes Care 2011;34:727-9.
15. Ahmed MH, Barakat S, Almobarak AO. Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists? J Obes 2012;2012:483135.
16. Kogiso T, Moriyoshi Y, Shimizu S, et al. High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike Information Criterion scoring system in the general Japanese population. J Gastroenterol 2009;44:313-21.
17. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010;22:347-52.
18. Tarantino G, Conca P, Pasanisi F, et al. Could inflammatory markers help diagnose nonalcoholic steatohepatitis? Eur J Gastroenterol Hepatol 2009;21:504-11.
19. Tarantino G, Savastano S, Capone D, et al. Spleen: a new role for an old player? World J Gastroenterol 2011;17:3776-84.
20. Lesmana CR, Hasan I, Budihusodo U, et al. Diagnostic value of a group of biochemical markers of liver fibrosis in patients with non-Alcoholic steatohepatitis. J Dig Dis 2009;10:201-6.
21. Maleki I, Aminafshari MR, Taghvaei T, et al. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-Alcoholic fatty liver disease. World J Gastroenterol 2014;20:12566-73.
22. Lee YJ, Lee HR, Shim JY, et al. Relationship between white blood cell count and nonalcoholic fatty liver disease. Dig Liver Dis 2010;42:888-94.
23. Lorenzo C, Hanley AJ, Haffner SM. Differential white cell count and incident type 2 diabetes: the insulin resistance atherosclerosis study. Diabetologia 2014;57:83-92.
24. Lohsoonthorn V, Dhanamun B, Williams MA. Prevalence of metabolic syndrome and its relationship to white blood cell count in a population of Thai men and women receiving routine health examinations. Am J Hypertens 2006;19:339-45.
25. Zeng MD, Fan JG, Lu LG, et al. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. J Dig Dis 2008;9:108-12.
26. Schunk D. A Markov chain Monte Carlo algorithm for multiple imputation in large surveys. AStA Adv Stat Anal 2008;92:101-14.
27. Das SK, Mukherjee S, Vasudevan DM, et al. Comparison of haematological parameters in patients with non-Alcoholic fatty liver disease and alcoholic liver disease. Singapore Med J 2011;52:175-81.
28. Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: state-of-The-Art. World J Gastroenterol 2014;20:13306-24.
29. Amarapurkar D, Kamani P, Patel N, et al. Prevalence of non-Alcoholic fatty liver disease: population based study. Ann Hepatol 2007;6:161-3.
30. Frith J, Day CP, Henderson E, et al. Non-Alcoholic fatty liver disease in older people. Gerontology 2009;55:607-13.
31. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-Alcoholic fatty liver disease and non-Alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274-85.
32. Chen ZW, Chen LY, Dai HL, et al. Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease. J Zhejiang Univ Sci B 2008;9:616-22.
33. Caballería L, Pera G, Auladell MA, et al. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. Eur J Gastroenterol Hepatol 2010;22:24-32.
34. Liu Y, Dai M, Bi Y, et al. Active smoking, passive smoking, and risk of nonalcoholic fatty liver disease (NAFLD): a population-based study in China. J Epidemiol 2013;23:115-21.
35. Nseir W, Hellou E, Assy N. Role of diet and lifestyle changes in nonalcoholic fatty liver disease. World J Gastroenterol 2014;20:9338-44.
36. Hu X, Huang Y, Bao Z, et al. Prevalence and factors associated with nonalcoholic fatty liver disease in Shanghai work-units. BMC Gastroenterol 2012;12:123.
37. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2007;25:883-9.
38. Loomba R, Abraham M, Unalp A, et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012;56:943-51.
39. Tarantino G, Finelli C. What about non-Alcoholic fatty liver disease as a new criterion to define metabolic syndrome? World J Gastroenterol 2013;19:3375-84.
40. Riquelme A, Arrese M, Soza A, et al. Nonalcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int 2009;29:82-8.
41. Nigam P, Bhatt SP, Misra A, et al. Non-Alcoholic fatty liver disease is closely associated with sub-clinical inflammation: a case-control study on Asian Indians in North India. PLoS ONE 2013;8:e49286.
42. Uchihara M, Izumi N. [High-sensitivity C-reactive protein (hs-CRP): a promising biomarker for the screening of non-Alcoholic steatohepatitis (NASH)]. Nippon Rinsho 2006;64:1133-8.
43. Park SH, Kim BI, Yun JW, et al. Insulin resistance and C-reactive protein as independent risk factors for non-Alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol 2004;19:694-8.
44. Das SK, Balakrishnan V. Role of cytokines in the pathogenesis of non-Alcoholic fatty liver disease. Indian J Clin Biochem 2011;26:202-9.
45. Tasci I, Dogru T, Ercin CN, et al. Adipokines and cytokines in non-Alcoholic fatty liver disease. Aliment Pharmacol Ther 2008;28:266-7.
46. Day CP, James OF. Steatohepatitis: a tale of two hits? Gastroenterology 1998;114:842-5.
47. Jimba S, Nakagami T, Takahashi M, et al. Prevalence of nonalcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 2005;22:1141-5.
48. Chao TT, Hsieh CH, Lin JD, et al. Use of white blood cell counts to predict metabolic syndrome in the elderly: a 4 year longitudinal study. Aging Male 2014;17:230-7.
49. Gharipour M, Ramezani MA, Sadeghi M, et al. Sex based levels of C-reactive protein and white blood cell count in subjects with metabolic syndrome: Isfahan Healthy Heart Program. J Res Med Sci 2013;18:467-72.
50. Botezelli JD, Mora RF, Dalia RA, et al. Exercise counteracts fatty liver disease in rats fed on fructose-rich diet. Lipids Health Dis 2010;9:116.
51. Wolf AM, Busch B, Kuhlmann HW, et al. Histological changes in the liver of morbidly obese patients: correlation with metabolic parameters. Obes Surg 2005;15:228-37.
52. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
53. Ballestri S, Romagnoli D, Nascimbeni F, et al. Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. Expert Rev Gastroenterol Hepatol 2015;9:603-27.
54. Ballestri S, Lonardo A, Romagnoli D, et al. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. Liver Int 2012;32:1242-52.
55. Sinn DH, Gwak GY, Park HN, et al. Ultrasonographically detected non-Alcoholic fatty liver disease is an independent predictor for identifying patients with insulin resistance in non-obese, non-diabetic middle-Aged Asian adults. Am J Gastroenterol 2012;107:561-7.